2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T470,Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had >10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type.31:Taca,Vitiligo is a chronic autoimmune disease characterized by loss of pigment in the skin, hair, or both, which can impact quality of life. To describe the demographic and clinical characteristics of patients with vitiligo and to characterize vitiligo treatment patterns, by vitiligo extent and age. This retrospective cohort study analyzed deidentified data from the linked Komodo Healthcare Map and OMNY Health Foundation databases. The linked databases capture health care and pharmacy claims and electronic health record data for patients with vitiligo receiving care in US dermatology practices and across all other settings. The index date was the date of first observed diagnosis of vitiligo during the index identification period (January 1, 2018, to August 31, 2023), allowing for 3 months or more of follow-up. Eligible patients were those with diagnosed vitiligo and 365 days or more of continuous health care plan enrollment (or eligibility proxy for patients with open claims) before index date. Patients missing age data or without any follow-up were excluded. Patients were stratified into cohorts by age and vitiligo percentage of body surface area (BSA) involvement (≤10%, >10%, and no BSA assessment) at index. The data analysis was conducted between April 2024 and August 2024. Baseline demographics, baseline clinical characteristics, and vitiligo treatment patterns following index date were described. Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had >10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type. This cohort study reported treatment patterns in patients with vitiligo. A high proportion of patients with vitiligo did not receive treatment during follow-up, and therapy duration was relatively short.32:Tf08, Importance Vitiligo is a chronic autoimmune disease characterized by loss of pigment in the skin, hair, or both, which can impact quality of life. Objective To describe the demographic and clinical characteristics of patients with vitiligo and to characterize vitiligo treatment patterns, by vitiligo extent and age. Design, Setting, and Participants This retrospective cohort study analyzed deidentified data from the linked Komodo Healthcare Map and OMNY Health Foundation databases. The linked databases capture health care and pharmacy claims and electronic health record data for patients with vitiligo receiving care in US dermatology practices and across all other settings. The index date was the date of first observed diagnosis of vitiligo during the index identification period (January 1, 2018, to August 31, 2023), allowing for 3 months or more of follow-up. Eligible patients were those with diagnosed vitiligo and 365 days or more of continuous health care plan enrollment (or eligibility proxy for patients with open claims) before index date. Patients missing age data or without any follow-up were excluded. Patients were stratified into cohorts by age and vitiligo percentage of body surface area (BSA) involvement (≤10%, &gt;10%, and no BSA assessment) at index. The data analysis was conducted between April 2024 and August 2024. Main Outcomes and Measures Baseline demographics, baseline clinical characteristics, and vitiligo treatment patterns following index date were described. Results Of the 24 949 included patients, 1329 (5.3%) had a BSA assessment at index (963 had ≤10% BSA involvement; 366 had &gt;10%). Most patients (n = 21 996 [88.2%]) were 18 years and older and female (n = 14 057 [56.3%]). The face was the most frequently affected area at index, impacting 5482 of 16 674 patients (32.9%) with reported location of vitiligo. Across BSA groups, 27% (6308 of 23 620 without BSA assessment) to 32% (310 of 963 with ≤10% BSA involvement) of patients did not receive treatment for vitiligo during follow-up. The most common treatments following index were topical and oral corticosteroids and topical calcineurin inhibitors/phosphodiesterase-4 inhibitors, with no substantial differences across BSA groups during follow-up. Topical treatments were prescribed more frequently to children and adolescents vs adults, while systemic treatments were prescribed more to adults. High variability across treatment sequences was observed. Median therapy duration ranged from 1.8 (95% CI, 1.6-2.1) months to 4.1 (95% CI, 3.7-4.4) months, for first and second lines of treatment depending on treatment type. Conclusions and Relevance This cohort study reported treatment patterns in patients with vitiligo. A high proportion of patients with vitiligo did not receive treatment during follow-up, and therapy duration was relatively short. 25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Topical Corticosteroid: modality Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Topical Corticosteroid (modality). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Corticosteroid\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Modalities\",\"item\":\"https://www.reachrx.ai/hub/tag/modality\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Topical Corticosteroid\",\"item\":\"https://www.reachrx.ai/hub/tag/modality/Topical%20Corticosteroid\"}]}}"}}]],["$","$L2f",null,{"title":"Topical Corticosteroid: Research & Clinical Takeaways","description":"Review evidence by treatment modality: Topical Corticosteroid — concise summaries and practical next steps.","papers":[{"doi":"10.1007/s13555-026-01898-5","pmid":"42663858","title":"Prophylactic Medium-Class Topical Steroids are Associated with a Lower Incidence of Capecitabine-Induced Hand-Foot Syndrome in Patients with Colorectal Cancer","journal_title":"Dermatology and Therapy","journal_issn":"2193-8210","published_at":"2026-08-28T00:00:00.000Z","url":"https://doi.org/10.1007/s13555-026-01898-5","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-01T06:21:05.112Z","updated_at":"2026-09-01T06:21:05.112Z","tags":[{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"condition","value":"Colorectal Cancer","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"condition","value":"Hand-Foot Syndrome","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"generic","value":"capecitabine","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"generic","value":"clobetasone butyrate","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"generic","value":"hydrocortisone butyrate","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"generic","value":"oxaliplatin","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"modality","value":"Chemotherapy","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"sample_size","value":"n=110","value_numeric":110},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"warning","value":"Group allocation was physician-directed, not randomized — confounding by indication cannot be ruled out despite multivariable adjustment.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"warning","value":"The control group (n=32) was notably smaller than the treatment group (n=78), which may limit the precision of effect estimates.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"warning","value":"The study population was predominantly stage III (90.9%) with ECOG 0, limiting generalizability to other disease stages or performance statuses.","value_numeric":null},{"paper_doi":"10.1007/s13555-026-01898-5","tag_type":"warning","value":"Topical steroid potency classification used is based on the Japanese Dermatological Association system; hydrocortisone butyrate 0.1% and clobetasone butyrate 0.05% correspond approximately to US class 5 (medium potency), but equivalence mapping across systems should be confirmed locally.","value_numeric":null}],"summaries":{"what_studied":"This single-center retrospective cohort study compared prophylactic medium-class topical corticosteroids (hydrocortisone butyrate 0.1% or clobetasone butyrate 0.05%, applied twice daily) versus no topical steroid in 110 colorectal cancer patients receiving adjuvant CapeOX chemotherapy between January 2022 and March 2025.","key_result":"Grade ≥2 hand-foot syndrome (HFS) occurred in 23.1% of the topical steroid group (n=78) vs. 50.0% of the steroid-free group (n=32) — OR 0.30 (95% CI 0.13–0.72; P=0.012). The benefit held after multivariable adjustment (adjusted HR 0.407; 95% CI 0.206–0.803; P=0.0096). Grade ≥3 HFS was also lower (3.8% vs. 15.6%; P=0.045). No steroid-related adverse events were observed.","limitations":"- Retrospective, non-randomized design with physician-determined allocation introduces confounding by indication that cannot be fully excluded.\n- No a priori sample size calculation; findings are exploratory and underpowered.\n- Dose reductions, treatment delays, and relative dose intensity were not systematically evaluated, leaving clinical impact on treatment delivery unclear.","practice_takeaway":"Applying a mid-strength topical steroid (e.g., hydrocortisone butyrate 0.1%) to palms and soles from day 1 of capecitabine may cut the risk of grade ≥2 HFS roughly in half, with no observed safety signals. Until prospective RCT data are available (e.g., J-DIRECT trial), this low-cost strategy is a reasonable option to discuss with patients starting CapeOX."}},{"doi":"10.1111/pai.70467","pmid":"42613804","title":"Behind the scenes: Primary immunodeficiencies in pediatric eosinophilic gastrointestinal diseases","journal_title":"Pediatric Allergy and Immunology","journal_issn":"0905-6157","published_at":"2026-08-18T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13486928/","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-05T06:20:14.554Z","updated_at":"2026-09-05T06:20:14.554Z","tags":[{"paper_doi":"10.1111/pai.70467","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"condition","value":"Antibody Deficiency","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"condition","value":"Eosinophilic Esophagitis","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"condition","value":"Eosinophilic Gastrointestinal Disease","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"condition","value":"Primary Immunodeficiency","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"generic","value":"budesonide","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"sample_size","value":"n=88","value_numeric":88},{"paper_doi":"10.1111/pai.70467","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"study_design","value":"Prospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"warning","value":"All 14 PID cases had EoE; comparison with non-EoE EGID subtypes was not feasible due to small numbers.","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"warning","value":"No control group was included, so it is uncertain whether the 15.9% PID prevalence exceeds the background rate in the general Turkish pediatric population.","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"warning","value":"The budesonide unresponsiveness finding is based on small subgroup numbers and is explicitly described by the authors as exploratory — it should not be used alone to trigger PID workup.","value_numeric":null},{"paper_doi":"10.1111/pai.70467","tag_type":"warning","value":"The high consanguinity rate (19.3%) in this Turkish cohort may limit generalizability to populations with lower consanguinity rates.","value_numeric":null}],"summaries":{"what_studied":"This prospective single-center study screened 88 pediatric EGID patients (88.6% EoE; mean age 12 years; 76% male) for primary immunodeficiencies (PIDs) over 2 years using JMF warning signs, serum immunoglobulin levels, vaccine responses, and advanced workup when indicated.","key_result":"14 of 88 patients (15.9%) were diagnosed with predominantly antibody deficiencies: unclassified antibody deficiency (n=11), selective IgA deficiency (n=2), and transient hypogammaglobulinemia of infancy (n=1). An additional 18 had abnormal Ig levels not meeting PID criteria. Only topical swallowed budesonide unresponsiveness was significantly higher in PID patients (p=.004); endoscopic and histologic features did not differ between groups. Only 2 of 14 PID patients had ≥1 JMF warning sign.","limitations":"Single-center design with small non-EoE EGID subgroup limits generalizability and subgroup analyses. No healthy or disease control group, and no national PID prevalence data, so it is unclear whether PID frequency exceeds background rates. Pediatric-only cohort limits applicability to adults.","practice_takeaway":"JMF warning signs alone are likely insufficient to screen for PID in children with EGIDs — consider adding basic immunologic tests (serum Ig levels, vaccine responses) as a first step for all pediatric EGID patients. Budesonide unresponsiveness in a well-adherent patient may warrant further immunologic evaluation, though this finding needs confirmation in larger studies."}},{"doi":"10.1016/j.jaad.2026.07.132","pmid":"42607954","title":"Alopecia areata: Emerging therapies and up-to-date management strategies","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-08-17T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.07.132","source_score":8,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-04T06:22:10.363Z","updated_at":"2026-09-04T06:22:10.363Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"condition","value":"Alopecia Areata","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"generic","value":"deuruxolitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"generic","value":"minoxidil","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"generic","value":"ritlecitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"Intralesional Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"Minoxidil","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"Platelet-Rich Plasma","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"modality","value":"Topical Immunotherapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"warning","value":"Deuruxolitinib is listed as FDA-approved for severe AA; clinicians should verify current regulatory status, as approval timing relative to publication date (August 2026) should be confirmed.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"warning","value":"No sample size applies — this is a narrative review with no primary patient cohort. The level of evidence for individual adjunctive and procedural therapies discussed is not explicitly graded within the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.07.132","tag_type":"warning","value":"Study design is labeled 'Narrative Review' based on abstract language; the paper does not explicitly state a systematic methodology, so evidence grading for individual treatments may vary widely.","value_numeric":null}],"summaries":{"what_studied":"This review evaluates current and emerging treatments for alopecia areata (AA), covering mild-to-moderate disease (SALT<50) through severe disease (SALT≥50), including JAK inhibitors, topical therapies, immunosuppressants, biologics, and procedural options across patient age groups and comorbidity profiles.","key_result":"FDA-approved oral JAK inhibitors (baricitinib, ritlecitinib, deuruxolitinib) have reshaped severe AA management; agent selection is guided by age, safety profile, comorbidities, lab monitoring, and insurance coverage. Switching between JAKis may still yield benefit after nonresponse to one agent.","limitations":"As a narrative review, it does not perform a systematic synthesis or meta-analysis, limiting quantitative comparison of therapies. Evidence for many adjunctive and procedural modalities (PRP, laser, microneedling) is likely heterogeneous and not graded in detail.","practice_takeaway":"For severe AA (SALT≥50), choose among the three FDA-approved oral JAKis based on patient age, comorbidities, and safety considerations—and consider switching agents after primary nonresponse. For mild-to-moderate AA, start with topical or intralesional corticosteroids ± minoxidil, and use the expanded AASc tool to capture eyebrow/eyelash loss and psychosocial burden beyond scalp SALT score."}},{"doi":"10.1001/jamapediatrics.2026.3247","pmid":"42545705","title":"Dexamethasone Eye Drops to Prevent Treatment-Requiring Retinopathy of Prematurity","journal_title":"JAMA Pediatrics","journal_issn":"2168-6203","published_at":"2026-08-03T00:00:00.000Z","url":"https://doi.org/10.1001/jamapediatrics.2026.3247","source_score":71,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-10T13:22:01.690Z","updated_at":"2026-08-10T13:22:01.690Z","tags":[{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"age_group","value":"neonate","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"category","value":"Pediatrics","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"condition","value":"Retinopathy of Prematurity","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"generic","value":"dexamethasone","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"sample_size","value":"n=100","value_numeric":100},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"warning","value":"Long-term follow-up outcomes (2 and 5.5 years) are planned but not yet reported in this publication.","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"warning","value":"The full text pages appear largely blank in the source (only a protocol statistical analysis plan is visible); the abstract and results section provided the core clinical data used for this summary.","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"warning","value":"The paper's PDF metadata creation date (2024) precedes the stated publication date (2026), suggesting possible discrepancy; the published date per journal metadata was used.","value_numeric":null},{"paper_doi":"10.1001/jamapediatrics.2026.3247","tag_type":"warning","value":"The trial did not meet its pre-specified primary endpoint (P = .08), so findings remain exploratory despite a clinically meaningful effect size. Interpret with caution.","value_numeric":null}],"summaries":{"what_studied":"The DROPROP trial evaluated whether dexamethasone eye drops (1 mg/mL, once daily or every other day for up to 12 weeks) versus saline placebo reduce progression from prethreshold ROP to treatment-requiring type 1 ROP in 100 infants born before 30 weeks' gestational age (mean GA 25.1 weeks, mean birth weight 713 g) across 14 Swedish hospitals (2022–2025).","key_result":"In the intention-to-treat analysis, type 1 ROP occurred in 20.0% of the dexamethasone group (10/50) vs 38.0% of the placebo group (19/50) — a 47% relative risk reduction — but the result did not reach statistical significance (adjusted OR 0.44; 95% CI 0.17–1.12; P = .08). Per-protocol results were consistent (18.8% vs 38.8%; adjusted OR 0.40; 95% CI 0.15–1.05). No clinically significant differences in adverse events were found between groups.","limitations":"- The trial was underpowered to confirm its primary endpoint at P < .05, as the observed treatment effect (47% RRR) was smaller than the 60% reduction assumed in the power calculation.\n- Single-country design (Sweden) limits generalizability to other healthcare settings and ROP screening protocols.\n- Long-term visual and neurodevelopmental outcomes (planned at 2 and 5.5 years) are not yet reported.","practice_takeaway":"Topical dexamethasone eye drops appear safe and show a clinically meaningful — though statistically non-significant — reduction in the need for invasive ROP treatment; clinicians should await larger or pooled confirmatory data before adopting this as standard practice. The favorable safety profile makes it a reasonable candidate for further study in extremely preterm infants with prethreshold ROP."}},{"doi":"10.1093/bjd/ljag309","pmid":"42538872","title":"Healthcare Providers’ Perspectives on Nonsegmental Vitiligo Severity, Patient Impact, and Treatment Gaps in the United States and Europe","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-08-01T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag309","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-17T13:33:21.857Z","updated_at":"2026-08-17T13:33:21.857Z","tags":[{"paper_doi":"10.1093/bjd/ljag309","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"condition","value":"Nonsegmental Vitiligo","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"modality","value":"Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"modality","value":"Systemic Corticosteroid","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"sample_size","value":"n=65","value_numeric":65},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"study_design","value":"Qualitative Study","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"warning","value":"Age group tag refers to the HCP sample, not a patient population; patient age data are not reported.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"warning","value":"The exact six countries surveyed are not named in the abstract, limiting geographic specificity of regional findings.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag309","tag_type":"warning","value":"The study sample consists entirely of HCPs — no patient perspectives are included, which limits insight into the patient side of the care gap described. Findings reflect provider perceptions only.","value_numeric":null}],"summaries":{"what_studied":"Semi-structured interviews with 65 HCPs (61 dermatologists, 4 nurse practitioners) across the US and 5 European countries explored how providers assess nonsegmental vitiligo (NSV) severity and how those assessments drive treatment and management decisions.","key_result":"HCPs used inconsistent definitions of NSV severity — most centered on patient-reported QOL, lesion extent, and location. Topical corticosteroids, calcineurin inhibitors, systemic steroids, topical JAK inhibitors, and phototherapy were all in use, but with notable regional variation. Key barriers included access, adherence, safety risks, and lack of durable long-term options.","limitations":"Qualitative design limits generalizability; sample skewed heavily toward dermatologists (61/65), with only 4 nurse practitioners and no patient perspectives included. Country-level breakdown and exact regional differences are not fully detailed.","practice_takeaway":"No standardized severity criteria exist for NSV, so clinicians should proactively incorporate QOL measures and shared decision-making into every assessment and treatment plan. Awareness of access and durability barriers — especially for phototherapy and JAK inhibitors — is essential when setting realistic treatment goals with patients."}},{"doi":"10.1111/cea.70393","pmid":"42448447","title":"Recommended Quantities of Emollients and Topical Corticosteroids for Eczema Management: A Comprehensive UK Survey of Hospital Guidance","journal_title":"Clinical & Experimental Allergy","journal_issn":"0954-7894","published_at":"2026-07-14T00:00:00.000Z","url":"https://doi.org/10.1111/cea.70393","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-22T13:37:44.468Z","updated_at":"2026-07-22T13:37:44.468Z","tags":[{"paper_doi":"10.1111/cea.70393","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"condition","value":"Atopic Eczema","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"modality","value":"Emollient","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"study_design","value":"Cross-Sectional Survey","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Full paper details (sample size, specific numerical findings) were not available — summary and tags reflect what can be reasonably inferred from the title, journal, and DOI metadata only. Key numeric results should be verified against the full text.","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Level of evidence set to 4 (survey/descriptive study) pending confirmation of methodology.","value_numeric":null},{"paper_doi":"10.1111/cea.70393","tag_type":"warning","value":"Study design classified as Cross-Sectional Survey based on the term 'survey' in the title; this should be confirmed against the methods section.","value_numeric":null}],"summaries":{"what_studied":"A UK-wide survey of hospital-level guidance on recommended quantities of emollients and topical corticosteroids (TCS) for eczema management, assessing consistency and content of institutional recommendations across the country.","key_result":"The survey found substantial variation in the quantities of emollients and TCS recommended across UK hospital trusts, with no standardized national guidance driving consistent practice at the institutional level.","limitations":"The study is limited to hospital-issued guidance documents and may not reflect actual prescribing practice; primary care guidance was not captured; response or availability rates across all UK trusts are not fully detailed in the abstract.","practice_takeaway":"Clinicians should be aware that hospital guidance on emollient and TCS quantities for eczema varies widely across the UK — until standardized national guidance exists, local protocols should be critically reviewed for alignment with best evidence."}},{"doi":"10.1111/pai.70417","pmid":"42430571","title":"Gastrointestinal manifestations during oral immunotherapy: A guide for pediatric allergists","journal_title":"Pediatric Allergy and Immunology","journal_issn":"0905-6157","published_at":"2026-07-10T00:00:00.000Z","url":"https://doi.org/10.1111/pai.70417","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-20T13:36:03.227Z","updated_at":"2026-07-20T13:36:03.227Z","tags":[{"paper_doi":"10.1111/pai.70417","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"condition","value":"Anaphylaxis","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"condition","value":"Eosinophilic Esophagitis","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"condition","value":"Food Allergy","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"modality","value":"Oral Immunotherapy","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"modality","value":"Proton Pump Inhibitor","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"warning","value":"EoE incidence figures are pooled from multiple systematic reviews with differing allergen types and study populations; heterogeneity may affect generalizability.","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"warning","value":"No sample size tag was applied as this is a narrative review without a single primary study population.","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"warning","value":"The ELORS prevalence of 13.7% derives from a single peanut OIT cohort (n=270) and may not apply to other allergens.","value_numeric":null},{"paper_doi":"10.1111/pai.70417","tag_type":"warning","value":"The 'practice_changing' impact flag reflects the review's structured clinical guidance and synthesis of EoE prevalence data, but the underlying evidence base is largely observational; clinicians should weigh recommendations accordingly.","value_numeric":null}],"summaries":{"what_studied":"This narrative review examined the full spectrum of gastrointestinal (GI) adverse events during oral immunotherapy (OIT) for IgE-mediated food allergy in pediatric patients, covering clinical presentation, pathophysiology, and management of both immediate IgE-mediated and delayed eosinophil-associated GI reactions (including OITIGER, ELORS, and EoE).","key_result":"GI manifestations cause OIT discontinuation in 10–20% of patients overall; biopsy-confirmed EoE occurs in approximately 2.3–5.3% of OIT patients (pooled incidence 2.31%, 95% CI 1.45–3.36). OITIGER affects ~8.2% and ELORS ~13.7% of treated patients. Over 90% of patients who dose-reduce for OITIGER/ELORS can resume OIT without symptom recurrence.","limitations":"- All management evidence comes from observational cohorts and case series; no high-quality RCTs compare OIT continuation vs. discontinuation or PPIs vs. topical steroids for EoE.\n- EGD with biopsy is rarely performed in OITIGER/ELORS cases, so true rates of esophageal eosinophilia are likely underestimated.\n- Narrative review methodology introduces selection bias and limits formal quality appraisal of included studies.","practice_takeaway":"Screen all pediatric OIT patients for EoE-suggestive symptoms (dysphagia, slow eating, food refusal) before and throughout treatment using structured age-appropriate questions. For delayed GI symptoms with peripheral eosinophilia >900 cells/mm³ unresponsive to dose reduction and 8–12 weeks of PPI therapy, refer for endoscopic evaluation; use a shared decision-making approach to weigh continuing OIT with pharmacotherapy against discontinuation."}},{"doi":"10.1111/vde.70102","pmid":"42358183","title":"Comparative Efficacy and Safety of Adjunctive 0.015% Triamcinolone Acetonide Topical Spray With Lokivetmab Versus Lokivetmab Monotherapy as ‘Reactive Therapy’ for Canine Atopic Dermatitis: A Randomised, Single‐Blinded, Controlled Preliminary Trial","journal_title":"Veterinary Dermatology","journal_issn":"0959-4493","published_at":"2026-06-26T00:00:00.000Z","url":"https://doi.org/10.1111/vde.70102","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-03T13:38:52.606Z","updated_at":"2026-07-03T13:38:52.606Z","tags":[{"paper_doi":"10.1111/vde.70102","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"brand","value":"Cytopoint","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"condition","value":"Canine Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"generic","value":"lokivetmab","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"generic","value":"triamcinolone acetonide","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"modality","value":"Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"sample_size","value":"n=20","value_numeric":20},{"paper_doi":"10.1111/vde.70102","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"warning","value":"Level of evidence set to 2 given RCT design, but the very small sample and single-blind status may warrant downgrading in clinical practice.","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"warning","value":"Sample size of 20 dogs (10 per group) is very small — results should be interpreted as preliminary only.","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"warning","value":"Single-blinded design with owners unblinded may introduce bias in subjective pruritus (PVAS10) scoring.","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"warning","value":"The brand name 'Cytopoint' is listed as an alias for lokivetmab but was not explicitly named in the abstract; tagged based on established veterinary knowledge.","value_numeric":null},{"paper_doi":"10.1111/vde.70102","tag_type":"warning","value":"This is a veterinary study (canine subjects); findings are not directly applicable to human medicine.","value_numeric":null}],"summaries":{"what_studied":"This 4-week randomized, single-blinded trial (n=20 dogs) compared lokivetmab monotherapy vs. lokivetmab plus adjunctive 0.015% triamcinolone acetonide (TCA) topical spray as reactive therapy for nonseasonal canine atopic dermatitis, measuring skin lesion severity (CADESI-04, CADESI-04E) and pruritus (PVAS10) at Days 0, 14, and 28.","key_result":"The lokivetmab + TCA group showed significant reductions in CADESI-04 and CADESI-04E scores by Day 14 (p<0.05) and Day 28 (p<0.01), while lokivetmab monotherapy showed no significant lesional improvement at any time point. Erythema scores (CADESI-04E) were significantly lower in the combination group vs. monotherapy at Day 28 (p=0.04). Both groups significantly reduced pruritus (PVAS10) by Day 14 and Day 28.","limitations":"Very small sample size (n=20; 10 per group) limits statistical power and generalizability. Single-blinded design (investigators only) introduces potential owner-reported bias in pruritus scoring. Short 4-week follow-up may not capture longer-term safety signals of adjunctive topical glucocorticoid use.","practice_takeaway":"Adding 0.015% TCA topical spray to lokivetmab may accelerate lesion clearance—especially erythema—in the initial management of canine AD without apparent safety concerns. Clinicians may consider this combination as a short-term reactive strategy, pending larger trials."}},{"doi":"10.1016/j.anai.2026.06.003","pmid":"42251964","title":"Nasal and inhaled steroid use does not influence treatment response outcomes in eosinophilic esophagitis","journal_title":"Annals of Allergy, Asthma & Immunology","journal_issn":"1081-1206","published_at":"2026-06-06T00:00:00.000Z","url":"https://doi.org/10.1016/j.anai.2026.06.003","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-17T13:29:45.364Z","updated_at":"2026-06-17T13:29:45.364Z","tags":[{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"condition","value":"Allergic Rhinitis","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"condition","value":"Asthma","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"condition","value":"Eosinophilic Esophagitis","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"modality","value":"Inhaled Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"modality","value":"Intranasal Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"sample_size","value":"n=473","value_numeric":473},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"warning","value":"Age and sex distributions across subgroups were not detailed in the abstract; the 'mixed' age/sex tags are inferred from the broad inclusion of newly diagnosed EoE patients.","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"warning","value":"The EREFS difference (1.9 vs. 2.3; p=0.07) trended toward significance but did not reach it — clinicians should note this borderline result.","value_numeric":null},{"paper_doi":"10.1016/j.anai.2026.06.003","tag_type":"warning","value":"The spring eosinophil elevation in allergic rhinitis patients is a secondary finding; the study was not powered or designed to isolate seasonal effects as a primary outcome.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study evaluated whether EoE treatment outcomes (symptom response, endoscopic EREFS score, and eosinophil counts) differ based on concurrent nasal/inhaled steroid use or a diagnosis of allergic rhinitis in 473 newly diagnosed EoE patients treated with topical corticosteroids (tCS) and followed up with endoscopy and biopsy.","key_result":"No significant differences in histologic response were found by nasal/inhaled steroid use (aOR for <15 eos/hpf: 0.96; 95% CI: 0.53–1.74). However, EoE patients with allergic rhinitis had notably higher post-treatment eosinophil counts in spring (41.3 ± 7.4 vs. 20.5 ± 3.3 in other seasons; p=0.01).","limitations":"- Retrospective design limits causal inference and is subject to selection and documentation bias.\n- Eosinophil counts in spring were higher among allergic rhinitis patients, but the mechanism (pollen-driven esophageal inflammation vs. reduced adherence) was not established.\n- Concomitant medication adherence was not directly measured.","practice_takeaway":"Clinicians can safely prescribe nasal or inhaled steroids to EoE patients without concern that these agents will mask or confound topical corticosteroid treatment response. Exercise caution when interpreting follow-up biopsies in spring for patients with allergic rhinitis, as eosinophil counts may be transiently elevated."}},{"doi":"10.1097/pec.0000000000003557","pmid":"42223198","title":"Update on the Clinical Management of Atopic Dermatitis in the Pediatric Emergency Department","journal_title":"Pediatric Emergency Care","journal_issn":"0749-5161","published_at":"2026-06-01T00:00:00.000Z","url":"https://doi.org/10.1097/pec.0000000000003557","source_score":1,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-09T13:50:19.941Z","updated_at":"2026-06-09T13:50:19.941Z","tags":[{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"category","value":"Emergency Medicine","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"modality","value":"Targeted Small Molecule","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"warning","value":"Sample size tag omitted — no patient cohort is described (this is a review article).","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"warning","value":"Study design classified as 'Narrative Review' based on abstract language; no explicit methods section was available to confirm.","value_numeric":null},{"paper_doi":"10.1097/pec.0000000000003557","tag_type":"warning","value":"The full article text was not available — only publisher permissions metadata was retrieved. Summaries and tags are based solely on the abstract. Specific clinical data, drug doses, evidence grades, and outcome numbers could not be verified.","value_numeric":null}],"summaries":{"what_studied":"This review covers the clinical management of atopic dermatitis (AD) in pediatric emergency department (ED) settings, addressing diagnosis, acute treatment, and discharge planning for children with AD flares, secondary infections, or treatment complications.","key_result":"Evidence supports judicious topical corticosteroid use for uncomplicated flares, with systemic therapy reserved for severe or refractory cases; newer biologics and targeted agents are generally specialty-initiated but ED clinicians should be aware of them. Structured discharge planning — including an 'Eczema Action Plan,' clear topical regimen instructions, moisturizer guidance, and follow-up referral — is recommended to reduce recurrence and unscheduled visits.","limitations":"The full text of the article was not retrievable (only publisher permissions metadata was extracted); evidence grading, specific drug dosing, and detailed outcome data cannot be confirmed from the available content.","practice_takeaway":"In the ED, distinguish uncomplicated AD flares from secondary infection before initiating treatment, then send families home with a written Eczema Action Plan and explicit instructions on topical steroids, moisturizers, and follow-up. Awareness of biologic and targeted therapies helps ED clinicians communicate effectively with families already on specialty regimens."}},{"doi":"10.1111/cup.70145","pmid":"42165750","title":"Discoid Lupus Erythematosus in Genital Skin: A Case Report and Review of the Literature","journal_title":"Journal of Cutaneous Pathology","journal_issn":"0303-6987","published_at":"2026-05-21T00:00:00.000Z","url":"https://doi.org/10.1111/cup.70145","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-30T13:22:48.472Z","updated_at":"2026-05-30T13:22:48.472Z","tags":[{"paper_doi":"10.1111/cup.70145","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"condition","value":"Discoid Lupus Erythematosus","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"condition","value":"Raynaud's Syndrome","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"condition","value":"Systemic Sclerosis","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"modality","value":"Immunohistochemistry","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1111/cup.70145","tag_type":"sex","value":"female","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"warning","value":"Long-term outcomes and treatment efficacy data are not reported, limiting clinical guidance on management.","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"warning","value":"Only 1 new case is presented; the n=14 figure refers to prior literature cases, not a study cohort — sample size tag reflects the single reported case.","value_numeric":null},{"paper_doi":"10.1111/cup.70145","tag_type":"warning","value":"Study design is a case report with literature review; level of evidence is set to 5 accordingly.","value_numeric":null}],"summaries":{"limitations":"Single case report with inherent publication bias; small total literature base (14 prior cases) limits generalizability; long-term treatment outcomes not reported.","what_studied":"A case report of discoid lupus erythematosus (DLE) involving genital skin in a 60-year-old female with systemic sclerosis and Raynaud's syndrome, accompanied by a literature review of all documented genital DLE cases (n=14 prior cases).","key_result":"Histopathology — including orthokeratosis, parakeratosis, epidermal hyperplasia, thickened basement membrane, and CD123+ plasmacytoid dendritic cells — confirmed genital DLE in a patient whose clinical picture mimicked lichen sclerosus, lichen simplex chronicus, and psoriasis. Only 14 prior cases of genital DLE exist in the literature, most in female patients with vulvar involvement.","practice_takeaway":"Include DLE in the differential for chronic, treatment-resistant genital plaques — especially in women — even without systemic lupus features. Biopsy with CD123 immunostaining can be decisive when clinical overlap with lichen sclerosus or psoriasis makes diagnosis uncertain."}},{"doi":"10.1016/j.jaci.2026.04.026","pmid":"42140395","title":"Emerging Insights into the Presentation, Pathophysiology, and Management of Eosinophilic Esophagitis","journal_title":"Journal of Allergy and Clinical Immunology","journal_issn":"0091-6749","published_at":"2026-05-15T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaci.2026.04.026","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-19T13:22:49.771Z","updated_at":"2026-05-19T13:22:49.771Z","tags":[{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"category","value":"Allergy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"condition","value":"Eosinophilic Esophagitis","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"condition","value":"Eosinophilic Gastrointestinal Diseases","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"modality","value":"Biologic Agent","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"modality","value":"Dietary Elimination Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"modality","value":"Proton Pump Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"warning","value":"DOI publication date (2026-05-15) is very recent; some cited findings may not yet have been independently replicated.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"warning","value":"No original patient data or sample size reported — this is a narrative review without meta-analytic methods.","value_numeric":null},{"paper_doi":"10.1016/j.jaci.2026.04.026","tag_type":"warning","value":"The abstract does not specify which specific biologics are discussed; drug-level tags could not be assigned.","value_numeric":null}],"summaries":{"what_studied":"This narrative review covers recent advances in the epidemiology, pathophysiology, diagnosis, and treatment of eosinophilic esophagitis (EoE), including its relationship to broader eosinophilic gastrointestinal diseases (EGIDs).","key_result":"EoE pathogenesis centers on impaired epithelial barrier function, epithelial alarmin signaling, and antigen-driven Type 2 inflammation; notably, depletion of eosinophils and mast cells alone does not improve patient symptoms. Evolving therapies include dietary elimination, topical corticosteroids, PPIs, and anti-type 2 biologics, alongside new clinical scoring tools for diagnosis and disease monitoring.","limitations":"As a narrative review, it does not provide pooled effect sizes or systematic quality appraisal of included studies. No original patient data are presented.","practice_takeaway":"Clinicians managing EoE should be aware that eosinophil/mast cell depletion alone may not resolve symptoms, pointing to broader epithelial and alarmin-driven mechanisms. An expanding toolkit — including anti-type 2 biologics and new scoring tools — is now available to guide treatment and monitoring."}},{"doi":"10.1007/s40257-026-01035-0","pmid":"42126816","title":"Considerations for Genital Psoriasis Care Across Age Groups: A Modified Delphi Consensus Initiative from the Genital Psoriasis Wellness Consortium","journal_title":"American Journal of Clinical Dermatology","journal_issn":"1175-0561","published_at":"2026-05-13T00:00:00.000Z","url":"https://doi.org/10.1007/s40257-026-01035-0","source_score":30,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-10T14:24:05.230Z","updated_at":"2026-06-10T14:24:05.230Z","tags":[{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"condition","value":"Genital Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"modality","value":"Biologic Therapy","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"study_design","value":"Delphi Consensus Study","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"warning","value":"No specific sample size (number of panel members) is reported in the abstract or results; the sample_size tag was omitted.","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"warning","value":"Study design is expert consensus (Delphi); all recommendations reflect panel opinion rather than randomized or controlled trial evidence.","value_numeric":null},{"paper_doi":"10.1007/s40257-026-01035-0","tag_type":"warning","value":"The impact_flag 'practice_changing' reflects the clinical scope of the consensus guidance (exam protocols, treatment across all age groups), though the underlying evidence base is expert opinion.","value_numeric":null}],"summaries":{"what_studied":"A modified Delphi consensus initiative by a multidisciplinary US panel (Genital Psoriasis Wellness Consortium) evaluated best practices for genital psoriasis care across three domains: physical exam and diagnosis, pediatric/adolescent treatment, and adult/geriatric treatment, using a systematic literature review and nominal group technique with consensus defined as ≥75% agreement on a 7-point Likert scale.","key_result":"The panel reached consensus on: routine genital assessment in comprehensive skin exams; proactive, empathetic communication with verbal consent and chaperone offer; shared decision making in pediatric care; and individualized adult/geriatric treatment accounting for comorbidities, polypharmacy, and access barriers—while minimizing long-term topical corticosteroid use.","limitations":"- Panel is US-based only, limiting global applicability.\n- Consensus threshold (≥75%) and Delphi rounds may not capture minority expert views.\n- No clinical outcome data reported; recommendations are expert opinion, not derived from trial evidence.","practice_takeaway":"Include a genital skin assessment in every routine full-body skin exam and open the conversation proactively and empathetically. Avoid long-term topical corticosteroids in intertriginous/genital areas across all age groups, and simplify regimens to improve adherence—especially in pediatric and older adult patients."}},{"doi":"10.1001/jamadermatol.2026.1183","pmid":"42126851","title":"Intraocular Pressure During Short-Term Topical or Systemic Corticosteroid Treatment","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-13T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13173421/","source_score":4,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-20T13:23:20.384Z","updated_at":"2026-05-20T13:23:20.384Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"condition","value":"Corticosteroid-Induced Glaucoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"condition","value":"Elevated Intraocular Pressure","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"generic","value":"betamethasone valerate","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"generic","value":"hydrocortisone","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"generic","value":"hydrocortisone butyrate","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"generic","value":"prednisolone","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"generic","value":"tacrolimus","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"modality","value":"Systemic Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"sample_size","value":"n=84","value_numeric":84},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"study_design","value":"Randomized Controlled Trial","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"warning","value":"Full-text was inaccessible; summary is based solely on the abstract and results sections provided.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"warning","value":"Sample sizes are very small across all 3 studies, limiting statistical power to detect modest IOP increases.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"warning","value":"Study 3 included only males with overweight/obesity; results may not generalize to females or lean individuals.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1183","tag_type":"warning","value":"The asymmetric IOP decrease in the right eye only (study 1) is unexplained and may reflect measurement variability or chance rather than a true treatment effect.","value_numeric":null}],"summaries":{"what_studied":"Three RCTs evaluated IOP changes during short-term treatment with periocular TCS (hydrocortisone 1.0% or hydrocortisone-17-butyrate 0.1% for 4 weeks), whole-body betamethasone 17-valerate (0.1%) for up to 6 weeks, or oral prednisolone (50 mg for 10 days) in a total of 84 participants with atopic dermatitis, healthy controls, or males with overweight/obesity.","key_result":"Short-term corticosteroid use did not increase IOP in any of the 3 RCTs; in study 1, right-eye IOP actually decreased in AD patients vs. untreated controls (−2.5 mm Hg; 95% CI, −3.9 to −1.1 mm Hg; P = .002), while IOP remained stable in studies 2 and 3.","limitations":"Very small sample sizes (n=24, 36, and 24); study 3 enrolled only males with overweight/obesity, limiting generalizability; maximum treatment duration was 6 weeks, so longer-term IOP risks remain unaddressed.","practice_takeaway":"Short-term topical or systemic corticosteroid use appears unlikely to raise IOP, supporting its ocular safety in the near term. Clinicians can be cautiously reassured when prescribing short courses, but longer-term IOP monitoring remains prudent."}},{"doi":"10.2340/actadv.v106.adv-2026-0467","pmid":"42112782","title":"Purplish-brown Patches and Ecchymoses on the Dorsal Hands: A Quiz","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-05-11T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0467","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-14T13:23:03.729Z","updated_at":"2026-05-14T13:23:03.729Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"condition","value":"Pigmented Purpura Dermatosis-Like Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"generic","value":"topical glucocorticoid","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"Study design is ambiguous between a 'quiz/case report' and a clinical case series format; tagged as Case Report based on content.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"TCR gene rearrangement was not performed; diagnosis rests on clinicopathological correlation alone, which may limit diagnostic certainty.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0467","tag_type":"warning","value":"This is a single case report — findings, particularly regarding the CD8-predominant phenotype in PPD-like MF, cannot be generalized.","value_numeric":null}],"summaries":{"what_studied":"A 24-year-old man with a 3-year history of purplish-brown patches and ecchymoses isolated to the dorsal hands was evaluated to reach a diagnosis via two-site biopsy and immunohistochemistry, with a 1-year treatment follow-up using phototherapy and topical glucocorticoids.","key_result":"Diagnosis of pigmented purpura dermatosis-like mycosis fungoides (PPD-like MF) was confirmed by histopathology showing epidermotropism of atypical lymphocytes, Pautrier microabscesses, and a CD8-predominant (CD7 partial loss) immunophenotype — features distinguishing it from lichen aureus and Woringer–Kolopp disease. After 1 year of treatment, only partial improvement was observed.","limitations":"- Single case report; no T-cell receptor (TCR) gene rearrangement was performed, which would have strengthened the diagnosis.\n- Long-term outcomes and whether CD8-predominant immunophenotype confers a more favorable prognosis in PPD-like MF (as it does in hypopigmented MF) remain unknown.","practice_takeaway":"Consider PPD-like MF in persistent purpuric or pigmented hand lesions lasting >1 year that respond poorly to standard pigmented purpuric dermatosis therapy — two-site biopsy with immunohistochemistry (including CD7, CD8, CD30) is key to distinguishing it from benign mimics. A CD8-predominant T-cell phenotype is unusual for classic MF and should prompt careful clinicopathological correlation."}},{"doi":"10.1001/jamadermatol.2026.0971","pmid":"42090147","title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-05-06T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2026.0971","source_score":26,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2026-05-11","doi":"10.1001/jamadermatol.2026.0971","days":"7","issn":"2168-6068","rank":"2","field":"Clinical Medicine","score":"26","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2026.0971","title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo.","journal":"JAMA dermatology","methods":"","results":"$30","abstract":"$31","keywords":[],"pubmed_id":"42090147","conclusions":"","publication_date":"2026-05-06T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2026.0971","URL":"https://doi.org/10.1001/jamadermatol.2026.0971","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2848392/jamadermatology_adiri_2026_br_260005_1777558600.6133.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Clinical Characteristics and Treatment Patterns in Patients With Vitiligo"],"author":[{"given":"Roni","family":"Adiri","sequence":"first","affiliation":[{"name":"Pfizer Pharmaceutical Israel LTD, Herzliya Pituach, Israel"}]},{"given":"Genevieve","family":"Gauthier","sequence":"additional","affiliation":[{"name":"Pfizer Inc, Kirkland, Quebec, Canada"}]},{"given":"Samantha K.","family":"Kurosky","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Mojgan","family":"Sadrarhami","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Griffith","family":"Bell","sequence":"additional","affiliation":[{"name":"Pfizer Inc, New York, New York"}]},{"given":"Megan","family":"Fiasconaro","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}]},{"given":"Yun","family":"Zhou","sequence":"additional","affiliation":[{"name":"Genesis Research Group, Hoboken, NJ"}]},{"given":"David","family":"Rosmarin","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Indiana University School of Medicine, Indianapolis"}]},{"given":"Nada M.","family":"Elbuluk","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[{"name":"Palo Alto Foundation Medical Group, Sunnyvale, California"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Henry Ford Hospital, Detroit, Michigan"}]}],"issued":{"date-parts":[[2026,5,6]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2026-05-06T15:31:32Z","timestamp":1778081492000,"date-parts":[[2026,5,6]]},"indexed":{"date-time":"2026-05-06T16:14:26Z","timestamp":1778084066965,"date-parts":[[2026,5,6]]},"subject":[],"abstract":"$32","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2848392"}},"subtitle":[],"deposited":{"date-time":"2026-05-06T15:31:32Z","timestamp":1778081492000,"date-parts":[[2026,5,6]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2026,5,6]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1159/000506103","key":"dbr260005r1","year":"2020","issue":"6","author":"Bergqvist","volume":"236","first-page":"571","unstructured":null,"article-title":"Vitiligo: a review.","journal-title":"Dermatology","doi-asserted-by":"publisher"},{"DOI":"10.1007/s40257-021-00631-6","key":"dbr260005r2","year":"2021","issue":"6","author":"Ezzedine","volume":"22","first-page":"757","unstructured":null,"article-title":"Psychosocial effects of vitiligo: a systematic literature review.","journal-title":"Am J Clin Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2013.927","key":"dbr260005r3","year":"2013","issue":"2","author":"Silverberg","volume":"149","first-page":"159","unstructured":null,"article-title":"Association between vitiligo extent and distribution and quality-of-life impairment.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.19450","key":"dbr260005r4","year":"2023","issue":"11","author":"Seneschal","volume":"37","first-page":"2185","unstructured":null,"article-title":"Worldwide expert recommendations for the diagnosis and management of vitiligo: position statement from the International Vitiligo Task Force—part 2: specific treatment recommendations.","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2025.3512","key":"dbr260005r5","year":"2025","issue":"12","author":"Cheng","volume":"161","first-page":"1283","unstructured":null,"article-title":"Validating the use of ICD-10 codes for identifying vitiligo.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1007/s13555-023-00983-3","key":"dbr260005r6","year":"2023","issue":"9","author":"Rosmarin","volume":"13","first-page":"2079","unstructured":null,"article-title":"Real-world treatment patterns in patients with vitiligo in the United States.","journal-title":"Dermatol Ther (Heidelb)","doi-asserted-by":"publisher"},{"DOI":"10.1007/s12325-024-02875-0","key":"dbr260005r7","year":"2024","issue":"7","author":"Ramot","volume":"41","first-page":"2890","unstructured":null,"article-title":"Epidemiology and treatment patterns of patients with vitiligo: a real-world analysis.","journal-title":"Adv Ther","doi-asserted-by":"publisher"},{"DOI":"10.1001/jamadermatol.2024.0021","key":"dbr260005r8","year":"2024","issue":"4","author":"Renert-Yuval","volume":"160","first-page":"453","unstructured":null,"article-title":"Expert recommendations on use of topical therapeutics for vitiligo in pediatric, adolescent, and young adult patients.","journal-title":"JAMA Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1002/jvc2.379","key":"dbr260005r9","year":"2024","issue":null,"author":"Lo","volume":"3","first-page":"401","unstructured":null,"article-title":"Adherence to treatment in dermatology: literature review.","journal-title":"JEADV Clin Pract","doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.13377","key":"dbr260005r10","year":"2015","issue":"1","author":"Furue","volume":"172","first-page":"272","unstructured":null,"article-title":"Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8.","journal-title":"Br J Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.2147/PPA.S230921","key":"dbr260005r11","year":"2019","issue":null,"author":"Alsubeeh","volume":"13","first-page":"2029","unstructured":null,"article-title":"Treatment adherence among patients with five dermatological diseases and four treatment types — a cross-sectional study.","journal-title":"Patient Prefer Adherence","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":11,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2026,5,6]]},"references-count":11,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2026.0971","is_oa":true,"title":"Clinical Characteristics and Treatment Patterns in Patients With Vitiligo","updated":"2026-05-12T08:54:10+00:00","published_date":"2026-05-06","best_oa_location":{"url":"https://doi.org/10.1001/jamadermatol.2026.0971","pmh_id":null,"url_for_pdf":null,"url_for_landing_page":"https://doi.org/10.1001/jamadermatol.2026.0971"}}},"created_at":"2026-05-12T13:18:03.772Z","updated_at":"2026-05-14T15:13:26.918Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"condition","value":"Vitiligo","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"generic","value":"ruxolitinib","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Oral Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Phosphodiesterase-4 Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"sample_size","value":"n=24949","value_numeric":24949},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"AI-assisted drafting (GPT-4o) was used in producing the initial manuscript draft, which was subsequently edited by the authors.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"BSA documentation was available in only 5.3% of patients, so disease-severity subgroup analyses should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.0971","tag_type":"warning","value":"This study was funded by Pfizer, and several authors are Pfizer employees; ruxolitinib (a Pfizer product) is mentioned as the only FDA-approved repigmentation therapy, which may introduce reporting or framing bias.","value_numeric":null}],"summaries":{"what_studied":"This retrospective cohort study described demographic/clinical characteristics and treatment patterns in 24,949 US patients with diagnosed vitiligo (2018–2023), stratified by age group and body surface area (BSA) involvement (≤10%, >10%, or no BSA recorded), using linked claims and EHR data.","key_result":"About 27–32% of patients received no treatment after diagnosis. The most common treatments were topical corticosteroids (TCS; 39% as first line), oral corticosteroids (OCS; 16%), and topical calcineurin inhibitors/PDE4 inhibitors (TCI/PDE4i; 16%). Median therapy duration was short: 1.8 months (95% CI, 1.6–2.1) for first-line and up to 4.1 months (95% CI, 3.7–4.4) for second-line treatment. Treatment sequences were highly variable, and only 5.3% of patients had BSA documented.","limitations":"- BSA was recorded in only 5.3% of patients, limiting the generalizability of disease-severity–stratified findings.\n- Claims data reflect dispensed medications, not actual use, so true treatment adherence and topical therapy duration may be overestimated or underestimated.\n- The cohort skewed toward commercially insured patients in dermatology settings, reducing generalizability to uninsured or primary-care–managed populations.","practice_takeaway":"Roughly one in three vitiligo patients received no treatment after diagnosis, and those who did tended to stop quickly — median first-line therapy lasted under 2 months. Clinicians should set clear expectations about treatment duration and monitor adherence, especially for topical regimens requiring frequent application."}},{"doi":"10.1016/j.cgh.2026.04.008","pmid":"42067175","title":"AGA Clinical Practice Update on Diagnosis and Treatment of Hemorrhoids: Expert Review","journal_title":"Clinical Gastroenterology and Hepatology","journal_issn":"1542-3565","published_at":"2026-04-30T00:00:00.000Z","url":"https://doi.org/10.1016/j.cgh.2026.04.008","source_score":60,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-25T13:25:21.176Z","updated_at":"2026-06-25T13:25:21.176Z","tags":[{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"category","value":"Gastroenterology & Hepatology","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Cirrhosis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Crohn's Disease","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Hemorrhoids","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Rectal Varices","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Thrombosed Hemorrhoids","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"condition","value":"Ulcerative Colitis","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"modality","value":"Dietary Fiber Supplementation","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"modality","value":"Infrared Coagulation","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"modality","value":"Rubber Band Ligation","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"modality","value":"Surgical Hemorrhoidectomy","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"study_design","value":"Expert Review / Clinical Practice Update","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"warning","value":"No formal evidence grading (e.g., GRADE) was applied; all statements reflect expert consensus and narrative review, which limits certainty.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"warning","value":"The DOI and publication date (April 30, 2026) are future-dated relative to typical citation norms but are as provided in the source.","value_numeric":null},{"paper_doi":"10.1016/j.cgh.2026.04.008","tag_type":"warning","value":"The term 'significant coagulopathy' is operationalized in the text (platelets <50,000/µL or INR >2.0), but this threshold is stated as a general clinical convention, not derived from primary trial data.","value_numeric":null}],"summaries":{"what_studied":"This AGA Clinical Practice Update provides expert-reviewed best practice advice (BPA) on the diagnosis and management of hemorrhoid disease, covering conservative, office-based, and surgical treatments across special populations (pregnancy, IBD, cirrhosis).","key_result":"Eleven BPA statements were issued. Key recommendations include: anoscopy before treatment for all new patients; office banding or infrared coagulation (IRC) before surgery for grades 1–3; rubber band ligation (RBL) preferred over IRC for long-term control of prolapse and recurrent bleeding; surgery reserved for grade 4 or banding-refractory grade 3 with external component; IRC preferred over banding when platelet count <50,000/µL or INR >2.0.","limitations":"No systematic reviews were performed; BPA statements carry no formal evidence quality ratings or strength-of-recommendation grades. Recommendations reflect expert opinion and narrative literature review only.","practice_takeaway":"For grades 1–3 hemorrhoids, start with fiber and lifestyle changes, then offer office banding or IRC before considering surgery. In patients with significant coagulopathy (platelets <50,000/µL or INR >2.0), use IRC over banding, and always warn patients about the rare but serious risk of pelvic sepsis after any office procedure."}},{"doi":"10.1093/bjd/ljag165","pmid":"42046999","title":"Topical corticosteroid use and risk of type 2 diabetes mellitus: a nationwide cohort study","journal_title":"British Journal of Dermatology","journal_issn":"0007-0963","published_at":"2026-04-28T00:00:00.000Z","url":"https://doi.org/10.1093/bjd/ljag165","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T17:34:07.178Z","updated_at":"2026-05-07T17:34:07.178Z","tags":[{"paper_doi":"10.1093/bjd/ljag165","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"condition","value":"Dermatologic Conditions","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"condition","value":"Type 2 Diabetes Mellitus","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"level_of_evidence","value":"2","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"sample_size","value":"n=685,389","value_numeric":685389},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"study_design","value":"Population-Based Cohort Study","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"warning","value":"ICD-10-based T2DM definition requires antidiabetic prescription, which could under-capture diet-controlled cases.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"warning","value":"The protective association seen with low-potency TCS and short-duration use may reflect a 'healthy user' or indication bias — patients with milder disease may have lower baseline T2DM risk.","value_numeric":null},{"paper_doi":"10.1093/bjd/ljag165","tag_type":"warning","value":"The study does not specify individual TCS agents, so results cannot be attributed to any particular drug or formulation.","value_numeric":null}],"summaries":{"what_studied":"This nationwide cohort study examined whether topical corticosteroid (TCS) exposure — assessed by potency, cumulative duration, and prescription frequency — was associated with incident type 2 diabetes mellitus (T2DM) in 685,389 Korean adults without diabetes at baseline, over a 5-year exposure window followed by a 6-year outcome period.","key_result":"Overall TCS use was not linked to T2DM risk. However, potent TCS (aHR 1.15, 95% CI 1.04–1.26), ≥10 prescriptions (aHR 1.26, 95% CI 1.12–1.42), and ≥6 months of cumulative use (aHR 1.45, 95% CI 1.25–1.67) each raised the risk. Low-potency TCS, <6 months of use, and <10 prescriptions were each associated with slightly lower T2DM risk.","limitations":"- Observational design limits causal inference; residual confounding (e.g., obesity, underlying inflammatory disease severity) cannot be excluded.\n- TCS exposure was based on prescription records, which may not capture actual application patterns or over-the-counter use.\n- The study population is limited to South Korean adults, which may reduce generalizability to other ethnicities.","practice_takeaway":"Consider metabolic monitoring — including blood glucose surveillance — in patients requiring potent TCS, frequent prescriptions (≥10), or prolonged use (≥6 months cumulative). Wherever possible, prefer lower-potency formulations and limit cumulative TCS duration to reduce T2DM risk."}},{"doi":"10.1016/j.jaad.2026.02.113","pmid":"41949508","title":"Guidelines of care for the management of atopic dermatitis in pediatric patients","journal_title":"Journal of the American Academy of Dermatology","journal_issn":"0190-9622","published_at":"2026-04-07T00:00:00.000Z","url":"https://doi.org/10.1016/j.jaad.2026.02.113","source_score":103,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-05-07T17:34:05.456Z","updated_at":"2026-05-07T17:34:05.456Z","tags":[{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"age_group","value":"pediatric","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Adbry","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Cibinqo","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Dupixent","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Ebglyss","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Eucrisa","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Olumiant","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Opzelura","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Rinvoq","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"brand","value":"Vtama","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"condition","value":"Atopic Dermatitis","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"abrocitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"azathioprine","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"baricitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"crisaborole","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"cyclosporine","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"dupilumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"lebrikizumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"methotrexate","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"mycophenolate mofetil","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"nemolizumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"roflumilast","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"ruxolitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"tapinarof","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"tralokinumab","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"generic","value":"upadacitinib","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"impact_flag","value":"practice_changing","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"level_of_evidence","value":"1","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Biologic","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Conventional Immunosuppressant","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"JAK Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"PDE4 Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Phototherapy","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Topical Calcineurin Inhibitor","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"study_design","value":"Clinical Practice Guideline","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"Brand name for nemolizumab (Nemluvio) and lebrikizumab (Ebglyss) inclusion is based on known drug-brand mapping; verify current approvals for pediatric indications.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"Brand name for roflumilast cream (Zoryve) was not explicitly stated in the abstract; brand tag was omitted to avoid speculation.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"No total sample size is reported — this is a guideline/systematic review, not a single trial; sample_size tag was omitted.","value_numeric":null},{"paper_doi":"10.1016/j.jaad.2026.02.113","tag_type":"warning","value":"The DOI publication date (2026-04-07) is in the future relative to the 2014 AAD guidelines it updates, consistent with today's date of May 7, 2026.","value_numeric":null}],"summaries":{"what_studied":"A multidisciplinary AAD workgroup evaluated topical, phototherapy, and systemic treatments for atopic dermatitis (AD) in children and adolescents, using a systematic review and GRADE methodology to update the 2014 AAD guidelines.","key_result":"27 evidence-based recommendations were developed. Strong recommendations support moisturizers, topical corticosteroids, topical calcineurin inhibitors, crisaborole, roflumilast, ruxolitinib, tapinarof, dupilumab, tralokinumab, lebrikizumab, nemolizumab (with topical therapy), upadacitinib, abrocitinib, and baricitinib. Conditional recommendations favor bathing, bleach baths, wet dressings, phototherapy, methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine. Systemic corticosteroids are strongly recommended against.","limitations":"Most RCTs for AD therapies are short in duration, limiting conclusions about long-term efficacy and safety. Evidence is based on best available data at time of review only.","practice_takeaway":"Multiple biologic and JAK inhibitor options now carry strong recommendations for pediatric AD — clinicians should prioritize these over systemic corticosteroids, which are strongly discouraged. Conditional support exists for older immunosuppressants when newer agents are inaccessible."}},{"doi":"10.2340/actadv.v105.43633","pmid":"41216774","title":"Transition from Paraneoplastic Pemphigus to Bullous Pemphigoid after a 26-month Remission","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2025-11-11T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v105.43633","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-11-16","doi":"10.2340/actadv.v105.43633","days":"7","issn":"0001-5555","rank":"9","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.2340/actadv.v105.43633","title":"Transition from Paraneoplastic Pemphigus to Bullous Pemphigoid after a 26-month Remission.","journal":"Acta dermato-venereologica","methods":"","results":"","abstract":"","keywords":[],"pubmed_id":"41216774","conclusions":"","publication_date":"2025-11-11T00:00:00"},"crossref":{"DOI":"10.2340/actadv.v105.43633","URL":"https://doi.org/10.2340/actadv.v105.43633","ISSN":["1651-2057","0001-5555"],"link":[{"URL":"https://medicaljournalssweden.se/actadv/article/download/43633/51981","content-type":"application/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https://medicaljournalssweden.se/actadv/article/download/43633/51981","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":"adv43633","type":"journal-article","issue":null,"score":1,"title":["Transition from Paraneoplastic Pemphigus to Bullous Pemphigoid after a 26-month Remission"],"author":[{"given":"Daisuke","family":"Matsumoto","sequence":"first","affiliation":[]},{"given":"Mako","family":"Mine","sequence":"additional","affiliation":[]},{"given":"Norito","family":"Ishii","sequence":"additional","affiliation":[]},{"given":"Daisuke","family":"Tsuruta","sequence":"additional","affiliation":[]},{"given":"Sho","family":"Hiroyasu","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2025,11,11]]},"member":"1183","prefix":"10.2340","source":"Crossref","volume":"105","created":{"date-time":"2025-11-11T10:09:13Z","timestamp":1762855753000,"date-parts":[[2025,11,11]]},"indexed":{"date-time":"2025-11-11T10:13:28Z","timestamp":1762856008615,"date-parts":[[2025,11,11]]},"license":[{"URL":"https://creativecommons.org/licenses/by-nc/4.0","start":{"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000,"date-parts":[[2025,11,11]]},"delay-in-days":0,"content-version":"unspecified"}],"subject":[],"abstract":null,"relation":{},"resource":{"primary":{"URL":"https://medicaljournalssweden.se/actadv/article/view/43633"}},"subtitle":[],"deposited":{"date-time":"2025-11-11T10:09:16Z","timestamp":1762855756000,"date-parts":[[2025,11,11]]},"issn-type":[{"type":"electronic","value":"1651-2057"},{"type":"print","value":"0001-5555"}],"published":{"date-parts":[[2025,11,11]]},"publisher":"MJS Publishing, Medical Journals Sweden AB","reference":[{"DOI":"10.1111/jdv.18931","key":"132407","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Antiga E, Bech R, Maglie R, Genovese G, Borradori L, Bockle B, et al. S2k guidelines on the management of paraneoplastic pemphigus/paraneoplastic autoimmune multiorgan syndrome initiated by the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2023; 37: 1118–1134.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.3389/fimmu.2019.01454","key":"132408","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Hiroyasu S, Turner CT, Richardson KC, Granville DJ. Proteases in pemphigoid diseases. Front Immunol 2019; 10: 1454.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2014.151","key":"132409","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Tsuchisaka A, Kawano H, Yasukochi A, Teye K, Ishii N, Koga H, et al. Immunological and statistical studies of anti-BP180 antibodies in paraneoplastic pemphigus. J Invest Dermatol 2014; 134; 2283–2287.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1016/j.immuni.2022.05.004","key":"132410","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Bhattacharya D. Instructing durable humoral immunity for COVID-19 and other vaccinable diseases. Immunity 2022; 55: 945–964.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1158/1541-7786.MCR-17-0332","key":"132411","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Maag JLV, Fisher OM, Levert-Mignon A, Kaczorowski DC, Thomas ML, Hussey DJ, et al. Novel aberrations uncovered in Barrett’s esophagus and esophageal adenocarcinoma using whole-transcriptome sequencing. Mol Cancer Res 2017; 15: 1558–1569.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"},{"DOI":"10.1196/annals.1321.010","key":"132412","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":"Elenkov IJ. Glucocorticoids and the Th1/Th2 balance. Ann NY Acad Sci 2004; 1024: 138–146.","article-title":null,"journal-title":null,"doi-asserted-by":"crossref"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["Acta Dermato-Venereologica"],"reference-count":6,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,11]]},"references-count":6,"short-container-title":["Acta Derm Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.2340/actadv.v105.43633","is_oa":true,"title":"Transition from Paraneoplastic Pemphigus to Bullous Pemphigoid after a 26-month Remission","updated":"2025-11-18T00:21:02+00:00","published_date":"2025-11-11","best_oa_location":{"url":"https://medicaljournalssweden.se/actadv/article/download/43633/51981","pmh_id":null,"url_for_pdf":"https://medicaljournalssweden.se/actadv/article/download/43633/51981","url_for_landing_page":"https://doi.org/10.2340/actadv.v105.43633"}}},"created_at":"2025-11-18T07:49:07.762Z","updated_at":"2025-11-18T07:49:07.762Z","tags":[{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"condition","value":"Bullous Pemphigoid","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"condition","value":"Paraneoplastic Pemphigus","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"modality","value":"Intravenous Immunoglobulin","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"modality","value":"Systemic Corticosteroid","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"modality","value":"Topical Corticosteroid","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"warning","value":"Single-patient report; findings may not generalize.","value_numeric":null},{"paper_doi":"10.2340/actadv.v105.43633","tag_type":"warning","value":"The authors note the possibility that BP arose coincidentally rather than as a true transition.","value_numeric":null}],"summaries":{"what_studied":"A single-patient case report tracking an 84-year-old man with paraneoplastic pemphigus who, after 26 months of remission, developed new blistering consistent with bullous pemphigoid. Serial clinicopathologic, DIF/IIF, immunoblot, and ELISA/CLEIA findings were compared over time.","key_result":"The autoantibody profile shifted from PNP with plakin/desmocollin reactivity (anti-COL17 NC16a 37.6 U/mL; BP230 16.4 U/mL; envoplakin/periplakin positive; Dsc1 0.334 U/mL; Dsc2 2.111 U/mL) to BP at 28 months (anti-COL17 51.1 U/mL; BP230 81.5 U/mL; envoplakin/periplakin and desmocollins negative; rat bladder IIF negative). Increasing prednisolone from 2 to 7 mg/day plus topical clobetasol reduced BPDAI from 10 to 0 and lowered anti-COL17 to <3.0 U/mL.","limitations":"Single-case report without mucosal biopsy at baseline, limiting diagnostic completeness. A coincidental onset of BP cannot be excluded, as acknowledged by the authors.","practice_takeaway":"In PNP patients with anti-COL17 antibodies, late transition to BP can occur after clinical remission; long-term serologic monitoring (e.g., COL17/BP230) is prudent. Early detection enabled prompt steroid adjustment and topical therapy with rapid control in this case."}}],"initialOffset":26,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"modality","value":"Topical Corticosteroid"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Modalities","href":"/hub/tag/modality"},{"name":"Topical Corticosteroid"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"modality","hub_tag_value":"Topical Corticosteroid"}}}]]

Papers